ArticleAIDS and behavior2026
Barriers and Facilitators to Equitable Implementation of Long-Acting Injectable PrEP for Racial, Gender and Sexual Minority Populations in NYC: The EquiPrEP Study.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Long-acting injectable cabotegravir (LAI-CAB) is a novel HIV pre-exposure prophylaxis (PrEP) modality found to significantly lower HIV risk in key populations. EquiPrEP was an observational implementation science study to examine multilevel barriers and facilitators to LAI-CAB implementation among Black and/or Latine MSM, Black and/or Latine cisgender women, and transgender and nonbinary persons. This study took place at the Pride Health Center (PHC) at NYC Health+Hospitals (H+H)/Bellevue in New York City (February 2023-February 2025). Sociodemographic and health related social needs screening data were collected from EquiPrEP participants via a survey. We conducted in-depth interviews with study participants (N=26) and implementers (N=25) guided by The Consolidated Framework for Implementation Research 2.0. Descriptive statistics were used to assess sociodemographics for all EquiPrEP participants versus those recruited for in-depth interviews. Qualitative data was analyzed using thematic content analysis. Comparing all EquiPrEP participants (N=129) with the subgroup (N=26), the subgroup was older, with more Black cisgender MSM, and transgender women, a higher percentage ever on oral PrEP, and referred from an external clinic. Facilitators included open communication among staff, a patient-centered culture of care delivery and the EquiPrEP Navigator. Barriers included distance to clinical services, financial issues and insurance access. EquiPrEP is one of the first LAI-CAB implementation studies for HIV prevention to center equitable access for communities with the highest burden of HIV and elucidate implementation determinants to LAI-CAB. Findings may inform future implementation strategies seeking to incorporate equity as part of LAI-PrEP care.
Indexed as
Identifiers
42786370What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.